collection
MENU ▼
Read by QxMD icon Read
search

Rheumatic diseases

shared collection
123 papers 1000+ followers
By Faye Kehler Family Physician and GP Anesthetist since 1987 interested in all aspects of Medicine
https://www.readbyqxmd.com/read/24907035/survival-of-disease-modifying-antirheumatic-drugs-used-as-the-first-antirheumatic-medication-in-the-treatment-of-ankylosing-spondylitis-in-finland-a-nationwide-population-based-register-study
#1
Heikki Relas, Hannu Kautiainen, Kari Puolakka, Lauri J Virta, Marjatta Leirisalo-Repo
The tight national drug reimbursement regulations in the treatment of ankylosing spondylitis (AS) in Finland lead to the practice that at least one traditional disease-modifying antirheumatic drug (DMARD), if not contraindicated, has been tried and has failed before a patient can be eligible for reimbursement of anti-tumour necrosis factor (TNF) treatment. The aim of the present study is to evaluate drug survival of the firstly prescribed DMARDs in patients with AS. All AS patients from January 1, 2000 to December 31, 2007 were collected from the nationwide drug reimbursement registry maintained by the Social Insurance Institution (SII)...
August 2014: Clinical Rheumatology
https://www.readbyqxmd.com/read/25363224/clinical-experience-with-pirfenidone-in-five-patients-with-scleroderma-related-interstitial-lung-disease
#2
Yukiko Miura, Takefumi Saito, Kazutaka Fujita, Yoshiya Tsunoda, Toru Tanaka, Hiroyuki Takoi, Yohei Yatagai, Shigen Rin, Akimasa Sekine, Kenji Hayashihara, Takahito Nei, Arata Azuma
Interstitial lung disease is the most common complication and cause of death among patients with scleroderma. Scleroderma-related interstitial lung disease has usually been treated with cyclophosphamide; however, its effect was evaluated to be modest and long-term administration of this drug is associated with adverse effects. Herein, we report our clinical experience of administering pirfenidone, which is an antifibrotic agent, in five patients with scleroderma-related interstitial lung disease. All patients demonstrated an increase in vital capacity...
October 20, 2014: Sarcoidosis, Vasculitis, and Diffuse Lung Diseases: Official Journal of WASOG
https://www.readbyqxmd.com/read/27370878/an-open-label-phase-ii-study-of-the-safety-and-tolerability-of-pirfenidone-in-patients-with-scleroderma-associated-interstitial-lung-disease-the-lotuss-trial
#3
RANDOMIZED CONTROLLED TRIAL
Dinesh Khanna, Carlo Albera, Aryeh Fischer, Nader Khalidi, Ganesh Raghu, Lorinda Chung, Dan Chen, Elena Schiopu, Margit Tagliaferri, James R Seibold, Eduard Gorina
OBJECTIVE: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This study was designed to evaluate the tolerability of the IPF treatment pirfenidone in SSc-ILD. The known gastrointestinal, skin, and liver adverse events (AE) of pirfenidone are of importance given the involvement of these organs in SSc. METHODS: All patients received pirfenidone and were randomized 1:1 to either a 2- or 4-week titration starting at 801 mg/day and finishing at a maintenance dose of 2403 mg/day...
September 2016: Journal of Rheumatology
https://www.readbyqxmd.com/read/27469583/mycophenolate-mofetil-versus-oral-cyclophosphamide-in-scleroderma-related-interstitial-lung-disease-sls-ii-a-randomised-controlled-double-blind-parallel-group-trial
#4
RANDOMIZED CONTROLLED TRIAL
Donald P Tashkin, Michael D Roth, Philip J Clements, Daniel E Furst, Dinesh Khanna, Eric C Kleerup, Jonathan Goldin, Edgar Arriola, Elizabeth R Volkmann, Suzanne Kafaja, Richard Silver, Virginia Steen, Charlie Strange, Robert Wise, Fredrick Wigley, Maureen Mayes, David J Riley, Sabiha Hussain, Shervin Assassi, Vivien M Hsu, Bela Patel, Kristine Phillips, Fernando Martinez, Jeffrey Golden, M Kari Connolly, John Varga, Jane Dematte, Monique E Hinchcliff, Aryeh Fischer, Jeffrey Swigris, Richard Meehan, Arthur Theodore, Robert Simms, Suncica Volkov, Dean E Schraufnagel, Mary Beth Scholand, Tracy Frech, Jerry A Molitor, Kristin Highland, Charles A Read, Marvin J Fritzler, Grace Hyun J Kim, Chi-Hong Tseng, Robert M Elashoff
BACKGROUND: 12 months of oral cyclophosphamide has been shown to alter the progression of scleroderma-related interstitial lung disease when compared with placebo. However, toxicity was a concern and without continued treatment the efficacy disappeared by 24 months. We hypothesised that a 2 year course of mycophenolate mofetil would be safer, better tolerated, and produce longer lasting improvements than cyclophosphamide. METHODS: This randomised, double-blind, parallel group trial enrolled patients from 14 US medical centres with scleroderma-related interstitial lung disease meeting defined dyspnoea, pulmonary function, and high-resolution CT (HRCT) criteria...
September 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27255492/cyclophosphamide-versus-mycophenolate-mofetil-in-scleroderma-interstitial-lung-disease-ssc-ild-as-induction-therapy-a-single-centre-retrospective-analysis
#5
Padmanabha D Shenoy, Manish Bavaliya, Sujith Sashidharan, Kaveri Nalianda, Sreelakshmi Sreenath
BACKGROUND: Scleroderma is a systemic autoimmune disease characterized mainly by skin manifestations and involvement of various visceral organs, especially the lungs. Lung involvement is the leading cause of mortality in patients with scleroderma. There are data to suggest that cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are effective in the management of scleroderma interstitial lung disease (SSc-ILD) but no head to head comparative data are available to date. METHODS: For the last 3 years, patients with SSc-ILD have been treated at our centre by protocol-based administration of intravenous CYC and MMF...
June 2, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/26577237/systemic-sclerosis-and-localized-scleroderma-current-concepts-and-novel-targets-for-therapy
#6
REVIEW
Oliver Distler, Antonio Cozzio
Systemic sclerosis (SSc) is a chronic autoimmune disease with a high morbidity and mortality. Skin and organ fibrosis are key manifestations of SSc, for which no generally accepted therapy is available. Thus, there is a high unmet need for novel anti-fibrotic therapeutic strategies in SSc. At the same time, important progress has been made in the identification and characterization of potential molecular targets in fibrotic diseases over the recent years. In this review, we have selected four targeted therapies, which are tested in clinical trials in SSc, for in depths discussion of their preclinical characterization...
January 2016: Seminars in Immunopathology
https://www.readbyqxmd.com/read/28283512/efficacy-of-biological-disease-modifying-antirheumatic-drugs-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-the-management-of-rheumatoid-arthritis
#7
REVIEW
Jackie L Nam, Kaoru Takase-Minegishi, Sofia Ramiro, Katerina Chatzidionysiou, Josef S Smolen, Désirée van der Heijde, Johannes W Bijlsma, Gerd R Burmester, Maxime Dougados, Marieke Scholte-Voshaar, Ronald van Vollenhoven, Robert Landewé
OBJECTIVES: To update the evidence for the efficacy of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) to inform European League Against Rheumatism (EULAR) Task Force treatment recommendations. METHODS: MEDLINE, EMBASE and Cochrane databases were searched for phase III or IV (or phase II, if these studies were lacking) randomised controlled trials (RCTs) published between January 2013 and February 2016. Abstracts from the American College of Rheumatology and EULAR conferences were obtained...
June 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28413064/systemic-sclerosis
#8
REVIEW
Christopher P Denton, Dinesh Khanna
Systemic sclerosis, also called scleroderma, is an immune-mediated rheumatic disease that is characterised by fibrosis of the skin and internal organs and vasculopathy. Although systemic sclerosis is uncommon, it has a high morbidity and mortality. Improved understanding of systemic sclerosis has allowed better management of the disease, including improved classification and more systematic assessment and follow-up. Additionally, treatments for specific complications have emerged and a growing evidence base supports the use of immune suppression for the treatment of skin and lung fibrosis...
October 7, 2017: Lancet
https://www.readbyqxmd.com/read/28303481/morphea-and-eosinophilic-fasciitis-an-update
#9
REVIEW
Jorre S Mertens, Marieke M B Seyger, Rogier M Thurlings, Timothy R D J Radstake, Elke M G J de Jong
Morphea, also known as localized scleroderma, encompasses a group of idiopathic sclerotic skin diseases. The spectrum ranges from relatively mild phenotypes, which generally cause few problems besides local discomfort and visible disfigurement, to subtypes with severe complications such as joint contractures and limb length discrepancies. Eosinophilic fasciitis (EF, Shulman syndrome) is often regarded as belonging to the severe end of the morphea spectrum. The exact driving mechanisms behind morphea and EF pathogenesis remain to be elucidated...
August 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/25684768/2014-update-of-the-canadian-rheumatology-association-spondyloarthritis-research-consortium-of-canada-treatment-recommendations-for-the-management-of-spondyloarthritis-part-ii-specific-management-recommendations
#10
Sherry Rohekar, Jon Chan, Shirley M L Tse, Nigil Haroon, Vinod Chandran, Louis Bessette, Dianne Mosher, Cathy Flanagan, Kevin J Keen, Karen Adams, Michael Mallinson, Carter Thorne, Proton Rahman, Dafna D Gladman, Robert D Inman
OBJECTIVE: The Canadian Rheumatology Association (CRA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) have collaborated to update the recommendations for the management of spondyloarthritis (SpA). METHODS: A working group was assembled and consisted of the SPARCC executive committee, rheumatologist leaders from SPARCC collaborating sites, Canadian rheumatologists from across the country with an interest in SpA (both academic and community), a rheumatology trainee with an interest in SpA, an epidemiologist/health services researcher, a member of the CRA executive, a member of the CRA therapeutics committee, and a patient representative from the Canadian Spondylitis Association...
April 2015: Journal of Rheumatology
https://www.readbyqxmd.com/read/26786198/diagnosis-of-giant-cell-arteritis-when-should-we-biopsy-the-temporal-artery
#11
Omar Hussain, Andrew McKay, Kevin Fairburn, Peter Doyle, Robert Orr
Giant cell arteritis (GCA) can be diagnosed histopathologically by biopsy of the temporal artery, and clinically using the 5-point score of the 1990 American College of Rheumatology (ACR) classification. We aimed to find out whether some patients are referred for biopsy unnecessarily. We audited all referrals (n=100) made to the Department of Oral and Maxillofacial Surgery over 34 months, and used the ACR classification to find out whether patients had had a clinical diagnosis of GCA at referral (ACR score: 3 or more)...
April 2016: British Journal of Oral & Maxillofacial Surgery
https://www.readbyqxmd.com/read/2202311/the-american-college-of-rheumatology-1990-criteria-for-the-classification-of-giant-cell-arteritis
#12
G G Hunder, D A Bloch, B A Michel, M B Stevens, W P Arend, L H Calabrese, S M Edworthy, A S Fauci, R Y Leavitt, J T Lie
Criteria for the classification of giant cell (temporal) arteritis were developed by comparing 214 patients who had this disease with 593 patients with other forms of vasculitis. For the traditional format classification, 5 criteria were selected: age greater than or equal to 50 years at disease onset, new onset of localized headache, temporal artery tenderness or decreased temporal artery pulse, elevated erythrocyte sedimentation rate (Westergren) greater than or equal to 50 mm/hour, and biopsy sample including an artery, showing necrotizing arteritis, characterized by a predominance of mononuclear cell infiltrates or a granulomatous process with multinucleated giant cells...
August 1990: Arthritis and Rheumatism
https://www.readbyqxmd.com/read/1975173/illustrated-histopathologic-classification-criteria-for-selected-vasculitis-syndromes-american-college-of-rheumatology-subcommittee-on-classification-of-vasculitis
#13
J T Lie
We describe the histopathologic criteria for the diagnosis of 7 selected vasculitis syndromes: polyarteritis nodosa, Churg-Strauss syndrome, Wegener's granulomatosis, hypersensitivity vasculitis, Henoch-Schönlein purpura, giant cell (temporal) arteritis, and Takayasu arteritis. The criteria apply to the stereotypical cases in each category; they were formulated after a review of submitted biopsy material from 278 of the 1,000 patients entered into the American College of Rheumatology Vasculitis Study Registry, and from prior experience with the pathologic diagnosis of vasculitis in 1,079 nonregistry patients...
August 1990: Arthritis and Rheumatism
https://www.readbyqxmd.com/read/20799290/role-of-ultrasonography-in-the-diagnosis-of-temporal-arteritis
#14
REVIEW
E L Ball, S R Walsh, T Y Tang, R Gohil, J M F Clarke
BACKGROUND: Temporal artery (TA) biopsy is the current standard for diagnosing temporal arteritis, but has limited sensitivity. Colour duplex ultrasonography is a newer, non-invasive method of diagnosing temporal arteritis. METHODS: A systematic review was performed of trials comparing TA biopsy with duplex ultrasonography. Duplex results (halo sign, stenosis or vessel occlusion) were compared with either TA biospy findings or the American College of Rheumatology research criteria for diagnosing temporal arteritis...
December 2010: British Journal of Surgery
https://www.readbyqxmd.com/read/22809782/validity-of-the-american-college-of-rheumatology-criteria-for-the-diagnosis-of-giant-cell-arteritis
#15
Ann P Murchison, Molly E Gilbert, Jurij R Bilyk, Ralph C Eagle, Victoria Pueyo, Robert C Sergott, Peter J Savino
PURPOSE: To assess the clinical utility of the American College of Rheumatology criteria for the diagnosis of giant cell arteritis (GCA) in patients with positive and negative temporal artery biopsies. DESIGN: Retrospective case series of all patients undergoing temporal artery biopsy. METHODS: Retrospective chart review of all patients seen in the Neuro-ophthalmology Service of the Wills Eye Institute undergoing biopsy. One hundred twelve patients were identified between October 2001 and May 2006...
October 2012: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/25802967/diagnostic-algorithm-for-patients-with-suspected-giant-cell-arteritis
#16
Mays A El-Dairi, Lan Chang, Alan D Proia, Thomas J Cummings, Sandra S Stinnett, M Tariq Bhatti
BACKGROUND: To identify clinical and laboratory factors contributing to the diagnosis of giant cell arteritis (GCA) and develop a diagnostic algorithm for the evaluation of GCA. METHODS: Retrospective review of 213 consecutive cases of temporal artery biopsy (TAB) seen at a single academic center over a 10-year period (2000-2009). Pathologic specimens were re-reviewed and agreement between the original and second readings was assessed. A composite clinical suspicion score was created by adding 1 point for each of the following criteria: anterior extracranial circulation ischemia, new onset headache, abnormal laboratory results (erythrocyte sedimentation rate, C-reactive protein (CRP), or platelet count), jaw claudication, abnormal or tender superficial temporal artery, constitutional symptoms, and polymyalgia rheumatica; one point was subtracted if a comorbid condition could explain a criterion...
September 2015: Journal of Neuro-ophthalmology: the Official Journal of the North American Neuro-Ophthalmology Society
https://www.readbyqxmd.com/read/25102371/giant-cell-arteritis-diagnostic-accuracy-of-mr-imaging-of-superficial-cranial-arteries-in-initial-diagnosis-results-from-a-multicenter-trial
#17
MULTICENTER STUDY
Thorsten Klink, Julia Geiger, Marcus Both, Thomas Ness, Sonja Heinzelmann, Matthias Reinhard, Konstanze Holl-Ulrich, Dirk Duwendag, Peter Vaith, Thorsten Alexander Bley
PURPOSE: To assess the diagnostic accuracy of contrast material-enhanced magnetic resonance (MR) imaging of superficial cranial arteries in the initial diagnosis of giant cell arteritis ( GCA giant cell arteritis ). MATERIALS AND METHODS: Following institutional review board approval and informed consent, 185 patients suspected of having GCA giant cell arteritis were included in a prospective three-university medical center trial. GCA giant cell arteritis was diagnosed or excluded clinically in all patients (reference standard [final clinical diagnosis])...
December 2014: Radiology
https://www.readbyqxmd.com/read/27733943/updates-in-anca-associated-vasculitis
#18
REVIEW
Christian Pagnoux
Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides are small-vessel vasculitides that include granulomatosis with polyangiitis (formerly Wegener's granulomatosis), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Renal-limited ANCA-associated vasculitides can be considered the fourth entity. Despite their rarity and still unknown cause(s), research pertaining to ANCA-associated vasculitides has been very active over the past decades. The pathogenic role of antimyeloperoxidase ANCA (MPO-ANCA) has been supported using several animal models, but that of antiproteinase 3 ANCA (PR3-ANCA) has not been as strongly demonstrated...
September 2016: European Journal of Rheumatology
https://www.readbyqxmd.com/read/27567298/myelitis-and-lupus-clinical-manifestations-diagnosis-and-treatment-review
#19
Edson Hernán Chiganer, Javier Pablo Hryb, Edgar Carnero Contentti
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple systems. Myelopathy is one of 19 neuropsychiatric syndromes related to SLE defined by the American College of Rheumatology. Although infrequent, it is a severe manifestation, leading to motor and sensory deficits, and sphincter dysfunction. The pathogenesis is not clearly known, but may be related to arterial thrombosis and vasculitis. Diagnosis is based on clinical findings, laboratory tests and the use of gadolinium-enhanced magnetic resonance imaging...
November 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/27638912/prevalence-incidence-and-prognosis-of-chronic-kidney-disease-classified-according-to-current-guidelines-a-large-retrospective-cohort-study-of-rheumatoid-arthritis-patients
#20
Takeshi Tokoroyama, Minoru Ando, Kyogo Setoguchi, Ken Tsuchiya, Kosaku Nitta
Background: The prevalence, incidence and prognosis of chronic kidney disease (CKD) have not been fully understood in rheumatoid arthritis (RA) patients. Methods: A retrospective cohort study was performed in 1077 RA patients from July 2004 to June 2014. CKD was defined as either proteinuria ≥1+ or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 or both, according to the current CKD classification with risk categories for future death, end-stage renal disease and cardiovascular disease...
December 1, 2017: Nephrology, Dialysis, Transplantation
label_collection
label_collection
3223
1
2
2016-09-22 00:21:31
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"